Analyst Michael Matson of Needham maintained a Buy rating on Insight Molecular Diagnostics, retaining the price target of $4.25.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Matson has given his Buy rating due to a combination of factors that highlight Insight Molecular Diagnostics’s promising future. The company is making significant strides with its GraftAssureIQ research use only test, which is performing well in the market. Furthermore, Insight Molecular Diagnostics is on track with its plans for the GraftAssureDx Kidney kitted test, aiming for a mid-2026 launch following FDA clearance.
Additionally, the company has entered Phase 3 of its development, involving a validation trial with approximately 125 patients. Insight Molecular Diagnostics is also expanding its reach by signing agreements with transplant centers, with a goal of having at least 20 centers in the US and Germany by the end of 2025. Financially, the company ended the second quarter of 2025 with $24 million in cash and is effectively managing its cash burn, which is expected to remain stable at $6 million per quarter until the commercial launch of GraftAssureDx.